Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in the United States.1 Most deaths from ASCVD occur in patients with preexisting ASCVD. Secondary prevention trials in patients with established ASCVD demonstrate that low-density lipoprotein cholesterol (LDL-C)–lowering therapy with statins reduces recurrent cardiovascular events. Recently, new nonstatin drugs, notably ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have been introduced as statin add-on drugs for LDL-C lowering. This article reviews evidence-based strategies for reducing LDL-C in secondary prevention.
Grundy SM, Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol–Secondary Prevention. JAMA Cardiol. 2019;4(6):589–591. doi:10.1001/jamacardio.2019.0911
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: